Adimab discovers and engineers antibodies for drug developers, including partners developing cancer medicines.
Adimab is an antibody discovery and engineering company. Ono Pharmaceutical announced a collaboration with Adimab to discover and develop antibody drugs in oncology. The agreement covers discovery against targets selected by Ono; Ono will evaluate and develop candidates and has an option to obtain exclusive rights to develop, manufacture and commercialise them worldwide. This is a research partnership, not evidence that an antibody from it improves cancer outcomes.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/